vTv Therapeutics (VTVT) Research & Development (2014 - 2026)

vTv Therapeutics (VTVT) has 13 years of Research & Development data on file, last reported at $9.0 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 217.24% year-over-year to $9.0 million; the trailing twelve-month figure through Mar 2026 stood at $24.0 million (up 104.73% YoY), and the FY2025 full-year result was $17.9 million, up 54.69% from the prior year.
• Research & Development improved to $9.0 million in Q1 2026, from $3.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $9.0 million in Q1 2026 to a low of $2.1 million in Q4 2023.
• A 5-year average of $3.8 million and a median of $3.2 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development slumped 46.06% in 2023 and soared 217.24% in 2026, its largest moves.
• Tracing VTVT's Research & Development over 5 years: stood at $4.0 million in 2022, then tumbled by 46.06% to $2.1 million in 2023, then grew by 4.49% to $2.2 million in 2024, then surged by 74.93% to $3.9 million in 2025, then soared by 129.73% to $9.0 million in 2026.
• Business Quant data shows VTVT's Research & Development at $9.0 million in Q1 2026, $3.9 million in Q4 2025, and $7.0 million in Q3 2025.